The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Open accessAbstract
Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. Objective: This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research. Methods: Taking a high-level perspective, we address both psychological and psychiatric risks, such as abuse liability and potential for dependence, as well as medical harms, including toxicity and overdose. We explore the evidence base for these adverse effects to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny. Results: Our review shows that medical risks are often minimal, and that many – albeit not all – of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context. Conclusions: This highlights the importance for clinicians and therapists to keep to the highest safety and ethical standards. It is imperative not to be overzealous and to ensure balanced media reporting to avoid future controversies, so that much needed research can continue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 4×
“…treatment (combined with psychotherapy) for obsessive compulsive disorder (OCD) (Moreno et al., 2006), treatment-resistant depression (TRD) (Carhart-Harris et al., 2016), smoking cessation (Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015), leading to an increasing body of…”
BackgroundInfluentialSelf-citationTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 6×
“Most earlier shortcomings are being addressed in recent trials, that is, in randomised placebo double-blind studies (Carhart-Harris et al., 2021; Mitchell et al., 2021).”
BackgroundInfluentialSelf-citationAnthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“…psychotherapy) for obsessive compulsive disorder (OCD) (Moreno et al., 2006), treatment-resistant depression (TRD) (Carhart-Harris et al., 2016), smoking cessation (Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015), leading to an increasing body of positive evidence being developed.”
BackgroundMDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 3×
“…psychotherapy) for obsessive compulsive disorder (OCD) (Moreno et al., 2006), treatment-resistant depression (TRD) (Carhart-Harris et al., 2016), smoking cessation (Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015), leading to an increasing body of positive evidence being developed.”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 3×
“…focus of much contemporary research, including as an efficacious treatment (combined with psychotherapy) for obsessive compulsive disorder (OCD) (Moreno et al., 2006), treatment-resistant depression (TRD) (Carhart-Harris et al., 2016), smoking cessation (Johnson et al., 2014) and alcoholism…”
BackgroundGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 4×
“Psychedelics are physiologically safe in humans when ingested at standard doses (Dos Santos et al., 2012; Gasser et al., 2014; Nichols, 2004; Nichols and Grob, 2018).”
BackgroundResultInfluentialLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 5×
“Using the Addiction Research Centre Inventory (ARCI), Johnson et al. (2018) found a major difference in the abuse potential associated with psychedelics, as compared with other substances that carry a high risk of compulsive pattern of repetitive use and abuse, as LSD and psilocybin were repeatedly…”
BackgroundMethodInfluentialPsychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Self-citationPsychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Self-citationHuman psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Effects of Schedule I drug laws on neuroscience research and treatment innovation
Nutt, D. J., King, L. A., & Nichols, D. E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3530 · Cited by 337
Self-citationComparison of acute lethal toxicity of commonly abused psychoactive substances
Gable, R. S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00744.x · Cited by 321
Psychedelic Psychiatry’s Brave New World
Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020) · Cell · doi:10.1016/j.cell.2020.03.020 · Cited by 319
Self-citationBouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 1×
“Today, research has repeatedly shown that psychedelics do not cause dependence or compulsive use (Halberstadt, 2015; Johnson et al., 2018; Morgenstern et al., 1994; Nichols, 2016).”
BackgroundADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. J. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 312
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 302
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958) · Experientia · doi:10.1007/bf02159243 · Cited by 282
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 2×
“…studies comparing ayahuasca users with matched controls have documented increased working memory and executive functioning in users (Bouso et al., 2012), supporting the idea that psychedelics have neuroplastic and neurogenic properties (Catlow et al., 2013; Jefsen et al., 2020; Ly et al., 2018).”
BackgroundLong-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257
Self-citationClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 1×
“With adequate inclusion and exclusion criteria and clinical supervision, adverse physiological reactions are minimal (Malleson, 1971; Muttoni et al., 2019).”
BackgroundLSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · cited 4×
“However, genetic polymorphisms of the CYP2D6 enzyme – responsible for breaking down many commonly used medicines – significantly influenced the pharmacokinetics and in part also the subjective effects of LSD (Holze et al., 2021).”
BackgroundResultInfluentialModern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · cited 1×
“The fast build-up of tolerance and lack of withdrawal symptoms has been repeatedly shown in the literature (e.g. Krebs and Johansen, 2013; Liechti, 2017; Nichols, 2004), except for ayahuasca, which leads to minimal tolerance (Dos Santos et al., 2012).”
Backgroundvan Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581980 · Cited by 229 · cited 1×
“These findings have been replicated in the Netherlands (Van Amsterdam and Van den Brink, 2010, Europe (Van Amsterdam et al., 2015) and Australia (Bonomo et al., 2019).”
ResultSelf-citationAssessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227 · cited 2×
“In comparison with other psychoactive drugs, psychedelics score consistently low in their abuse potential (Fábregas et al., 2010).”
BackgroundResultAday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224 · cited 3×
“A recent systematic review found that individuals high in the traits of absorption, openness and acceptance as well as a state of surrender were more likely to have positive experiences with psychedelics, whereas individuals low in those domains or in a preoccupied/apprehensive state were more likely to experience acu…”
BackgroundSelf-citationThe Current Status of Psychedelics in Psychiatry
Nutt, D., & Carhart-Harris, R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2171 · Cited by 223
Self-citationKettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221
Hallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219
Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 215
Self-citationHarm potential of magic mushroom use: A review
Amsterdam, J. V., Opperhuizen, A., & Brink, W. V. D. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2011.01.006 · Cited by 208
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · cited 3×
“Indolethylamine N-methyltransferase (INMT), the enzyme synthesising DMT from tryptamine, is widely found in the human body, although its physiological role is still unclear (Garcia-Romeu et al., 2016).”
BackgroundGRIFFITHS, R. R., BRADY, J. V., & BRADFORD, L. D. (1979) · Advances in Behavioral Pharmacology · doi:10.1016/b978-0-12-004702-4.50010-2 · Cited by 197
Chromosomal Damage in Human Leukocytes Induced by Lysergic Acid Diethylamide
Cohen, M. M., Marinello, M. J., & Back, N. (1967) · Science · doi:10.1126/science.155.3768.1417 · Cited by 195
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D., & Pope, H. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.038 · Cited by 187
Psychedelics in the treatment of unipolar mood disorders: a systematic review
Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116679368 · Cited by 185
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
Gashi, L., Sandberg, S., & Pedersen, W. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102997 · Cited by 170
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
Singleton, S. P., Luppi, A. I., Carhart-Harris, R. L., Cruzat, J., Roseman, L., Nutt, D. J., Deco, G., Kringelbach, M. L., Stamatakis, E. A., & Kuceyeski, A. F. (2022) · Nature Communications · doi:10.1038/s41467-022-33578-1 · Cited by 167
Self-citationEl-Seedi, H. R., Smet, P. A. G. M. D., Beck, O., Possnert, G., & Bruhn, J. G. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.04.022 · Cited by 163
The Australian drug harms ranking study
Bonomo, Y., Norman, A., Biondo, S., Bruno, R., Daglish, M., Dawe, S., Egerton-Warburton, D., Karro, J., Kim, C., Lenton, S., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119841569 · Cited by 154
Self-citationPsychoactive Substances in Prehistoric Times: Examining the Archaeological Evidence
Doce, E. G. (2015) · Time and Mind · doi:10.1080/1751696x.2014.993244 · Cited by 150
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
Dishotsky, N. I., Loughman, W. D., Mogar, R. E., & Lipscomb, W. R. (1971) · Science · doi:10.1126/science.172.3982.431 · Cited by 142
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141 · cited 4×
“The fast build-up of tolerance and lack of withdrawal symptoms has been repeatedly shown in the literature (e.g. Krebs and Johansen, 2013; Liechti, 2017; Nichols, 2004), except for ayahuasca, which leads to minimal tolerance (Dos Santos et al., 2012).”
BackgroundResultInfluentialTriptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review
Gillman, P. K. (2009) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01575.x · Cited by 140
Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138
Serotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138 · cited 1×
“Most researchers now consider classic psychedelics to be non-toxic, that is, they do not damage mammalian organ systems, and as physiologically safe, even in very high doses (Gable, 2004; Halpern et al., 2005; Halpern and Pope, 1999; Malcolm and Thomas, 2021; Nichols, 2004).”
BackgroundShalit, N., Rehm, J. T., & Lev‐Ran, S. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.020 · Cited by 134
Halpern, J. H., Lerner, A. G., & Passie, T. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_457 · Cited by 133 · cited 3×
“Although Halpern and Pope (2003) suggest that there may be no identifiable risk factors for HPPD, a subsequent study of 19 individuals who developed HPPD found that all recalled anxiety and/or panic reactions during the triggering episode (Halpern et al., 2016).”
BackgroundCarbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133 · cited 1×
“, 2020, 2021), psilocybin (Carbonaro et al., 2018), ayahuasca (Dos Santos et al.”
BackgroundLSD Revisited: A Ten-Year Follow-up of Medical LSD Use
McGlothlin, W. H., & Arnold, D. O. (1971) · Archives of General Psychiatry · doi:10.1001/archpsyc.1971.01750070037005 · Cited by 130
Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00200-6 · Cited by 130
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Comparison of psilocin with psilocybin, mescaline and LSD-25
Wolbach, A. B., Miner, E. J., & Isbell, H. (1962) · Psychopharmacology · doi:10.1007/bf00412109 · Cited by 126
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124 · cited 1×
“However, recent naturalistic and online survey studies indicated that users report mental health benefits, such as reported improvements in depression and anxiety, related to its use (Agin-Liebes et al., 2021; Uthaug et al., 2021).”
BackgroundReport on psychoactive drug use among adolescents using ayahuasca within a religious context.
Doering-Silveira, E., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Da Silveira, D. X. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399794 · Cited by 122
N,N-Dimethyltryptamine: An Endogenous Hallucinogen
Barker, S. A., Monti, J. A., & Christian, S. T. (1981) · International review of neurobiology · doi:10.1016/s0074-7742(08)60291-3 · Cited by 117
Carhart-Harris, R. L., & Nutt, D. (2010) · Journal of Substance Use · doi:10.3109/14659890903271624 · Cited by 115
Self-citationPsilocybin, psychological distress, and suicidality
Hendricks, P. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115598338 · Cited by 114
Nichols, D. E., & Grob, C. S. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.01.006 · Cited by 113
Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom
Malleson, N. (1971) · British Journal of Psychiatry · doi:10.1192/bjp.118.543.229 · Cited by 111 · cited 5×
“The dose (Gable, 2004), route of administration and likelihood of any underlying health condition/s (Malleson, 1971) also determine potential adverse effects, such as multi-organ failure, hyperthermia and intoxication leading to other risky behaviours (Nichols and Grob, 2018; Van Amsterdam et al.,…”
BackgroundInfluentialGable, R. S. (1993) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999309001618 · Cited by 108
WINSTOCK, A. R., Kaar, S. J., & Borschmann, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113513852 · Cited by 107
Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
SANTOS, R. G. D. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.763564 · Cited by 104
A Controlled Study of Lysergide in the Treatment of Alcoholism. I . The Effects on Drinking Behavior
Smart, R. G., Storm, T., Baker, E. F. W., & Solursh, L. P. (1966) · Quarterly Journal of Studies on Alcohol · doi:10.15288/qjsa.1966.27.469 · Cited by 100
Baggott, M. J., Coyle, J., Erowid, E., Erowid, F., & Robertson, L. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.006 · Cited by 99
Tai, S. J., Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R.-L., Winzer, R., Richards, W. A., Reinholdt, F., Richards, B. D., Gasser, P., & Malievskaia, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.586682 · Cited by 90 · cited 1×
“Training and experience of the therapists (both during the dosing sessions and for the all-important integration sessions) is also essential (Tai et al., 2021).”
BackgroundNew World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
McKenna, D. J., & Riba, J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_472 · Cited by 88
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85 · cited 1×
“In Europe, a special use programme for d-lysergic acid diethylamide (LSD) and psilocybin has been established in Switzerland to provide compassionate access to (mainly major depression and post-traumatic stress disorder (PTSD)) patients not responding to other treatments (Schmid et al., 2021).”
BackgroundKendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb07243.x · Cited by 84
Lysergic Acid Diethylamide (LSD-25) as a Facilitating Agent in Psychotherapy
CHANDLER, A. L. (1960) · Archives of General Psychiatry · doi:10.1001/archpsyc.1960.03590090042008 · Cited by 84
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82
Harms associated with psychoactive substances: findings of the UK National Drug Survey
Morgan, C. J. A., Muetzelfeldt, L., Muetzelfeldt, M., Nutt, D., & Curran, H. V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106915 · Cited by 80
Self-citationMorgenstern, J., Langenbucher, J. W., & Labouvie, E. W. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb02787.x · Cited by 78
Heffter, A. (1898) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf01825267 · Cited by 78
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 77
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Zeifman, R. J., Singhal, N., Breslow, L., & Weissman, C. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00024 · Cited by 73
2019: A year of expansion in psychedelic research, industry, and deregulation
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2020) · Drug Science Policy and Law · doi:10.1177/2050324520974484 · Cited by 70
Self-citationBringing Ayahuasca to the Clinical Research Laboratory
Riba, J., & Barbanoj, M. J. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399804 · Cited by 63
Durante, Í., SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0913 · Cited by 62
Chromosomal Damage in LSD Users
Egozcue, J. (1968) · JAMA · doi:10.1001/jama.1968.03140160024006 · Cited by 57
Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey
Carhart-Harris, R. L., & Nutt, D. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.825034 · Cited by 54
Self-citationMagaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 54
Plants of the Gods: Origins of Hallucinogenic Use
Liskow, B. I. (1980) · JAMA · doi:10.1001/jama.1980.03310170076041 · Cited by 51
A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient
Lim, T. H., Wasywich, C. A., & Ruygrok, P. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02955.x · Cited by 50
Stone, A. L., Storr, C. L., & Anthony, J. C. (2006) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.188 · Cited by 40
Suicide During an LSD Reaction
KEELER, M. H., & Reifler, C. B. (1967) · American Journal of Psychiatry · doi:10.1176/ajp.123.7.884 · Cited by 40
Psychoactive sacramentals: Essays on entheogens and religion.
Roberts, T. B. (2001) · Cited by 40
Some observations on psilocybin, a new hallucinogen, in volunteer subjects
Malitz, S., Esecover, H., Wilkens, B., & Hoch, P. H. (1960) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(60)80045-4 · Cited by 38
HALLUCINOGENIC DRUGS AND CEREBRAL DEFICIT
Acord, L. D., & BARKER, D. D. (1973) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197304000-00009 · Cited by 38
Singleton, S. P., Luppi, A. I., Carhart-Harris, R. L., Cruzat, J., Roseman, L., Nutt, D. J., Deco, G., Kringelbach, M. L., Stamatakis, E. A., & Kuceyeski, A. F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.14.444193 · Cited by 36
Self-citationHonyiglo, E., Franchi, A., Cartiser, N., Bottinelli, C., Advenier, A., Bévalot, F., & Fanton, L. (2019) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13982 · Cited by 35
LSD and ketanserin and their impact on the human autonomic nervous system
Olbrich, S., Preller, K. H., & Vollenweider, F. X. (2021) · Psychophysiology · doi:10.1111/psyp.13822 · Cited by 34
The effects of psychedelic (LSD) therapy on values, personality, and behavior.
Savage, C., Fadiman, J., Mogar, R. E., & Allen, M. H. (1966) · PubMed · Cited by 33
Goodwin, A. K. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.07.004 · Cited by 31
2018: A watershed year for psychedelic science
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2019) · Drug Science Policy and Law · doi:10.1177/2050324519872284 · Cited by 31
Self-citationEgozcue, J. (1968) · JAMA · doi:10.1001/jama.204.3.214 · Cited by 27
Carroll, M. E. (1990) · Advances in Alcohol & Substance Abuse · doi:10.1300/j251v09n01_10 · Cited by 25
Experimental Psychiatry. V — Psilocybine, a New Psychotogenic Drug
Rinkel, M., Atwell, C. R., DiMascio, A., & Brown, J. L. (1960) · New England Journal of Medicine · doi:10.1056/nejm196002112620606 · Cited by 22
Germann, C. B. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109406 · Cited by 22
Martin, W. R. (1973) · Bayer-Symposium · doi:10.1007/978-3-642-87987-6_17 · Cited by 20 · cited 1×
“Psilocybin has been evaluated, together with LSD in various preclinical models of dependence and abuse potential, yielding qualitatively similar results, with no physical dependence or withdrawal (Martin, 1973).”
ResultHallucinogenic Drugs and Brain Damage
Acord, L. D. (1972) · Military Medicine · doi:10.1093/milmed/137.1.18 · Cited by 20
Ranking of drugs: a more balanced risk-assessment
van Amsterdam, J., & van den Brink, W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62000-4 · Cited by 17
A rare case of physical dependence with psychedelic LSD - A case report
Modak, T., Bhad, R., & Rao, R. (2019) · Journal of Substance Use · doi:10.1080/14659891.2019.1581286 · Cited by 8
Psicosis por consumo de ayahuasca: un reporte de caso
Tapia, H. R. C., Guzmán, M. A. G., & Ortiz, S. A. C. (2021) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2020.11.014 · Cited by 6
Psychiatric Drug Discovery and Development
Shahid, M., Neill, J. C., & Hutchison, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.004 · Cited by 5
Self-citation
Cited by
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“A recent non-systematic, narrative review explored the evidence base for the most frequently mentioned AEs in public discourse, to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny (Schlag et al., 2022).”
BackgroundPsychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60
“…(Erritzoe et al., 2017; Malleson, 1971; McWilliams and Tuttle, 1973; Strassman, 1984), stressful or suboptimal use-contexts (Carbonaro et al., 2016; Schlag et al., 2022), or occurred in individuals with previous or close family history of psychotic disorders (Anastasopoulos and Photiades, 1962;…”
BackgroundInfluentialPsychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Self-citationPepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Calder, A. E., & Hasler, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.091 · Cited by 28
Metadata
- Authors
- Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-02-02
- Volume
- 36
- Issue
- 3
- Pages
- 258-272
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4210376981
- Cited by
- 325
- References
- 131
- FWCI
- 60.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.